Brief: Genscript Submits Application With FDA For Use Of Cpass Sars-Cov-2 Neutralization Antibody Test In Convalescent Plasma Screening
13/01/2021 15:31
Jan 13 (Reuters) - Genscript Biotech Corp 1548.HK :
* GENSCRIPT SUBMITS APPLICATION WITH FDA FOR USE OF CPASS™
SARS-COV-2 NEUTRALIZATION ANTIBODY TEST IN CONVALESCENT PLASMA
SCREENING
Source text for Eikon: ID:nPn37cWqma
Further company coverage: 1548.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genscript Biotech
See all newsBrief: Genscript Launches Life Sciences Startup Pitchfest With Nvidia For Biotech Innovation
GenScript Biotech extends gain to hit near 5-year peak on Eli Lilly deal
GenScript Biotech hits near 5-year high on Eli Lilly collaboration
Brief: ProBio & Kun Tuo Announce Strategic Collaboration To Deliver Integrated CDMO-CRO Solutions
HK-listed GenScript Biotech drops on discounted share sale